Enhanced survival and mucosal repair after dextran sodium sulfate-induced colitis in transgenic mice that overexpress growth hormone

被引:214
作者
Williams, KL [1 ]
Fuller, CR
Dieleman, LA
DaCosta, CM
Haldeman, KM
Sartor, RB
Lund, PK
机构
[1] Univ N Carolina, Dept Cell & Mol Physiol, Chapel Hill, NC 27599 USA
[2] Univ N Carolina, Dept Pediat, Chapel Hill, NC 27599 USA
[3] Univ N Carolina, Dept Med, Chapel Hill, NC 27599 USA
[4] Univ N Carolina, Ctr Gastrointestinal Biol & Dis, Chapel Hill, NC 27599 USA
关键词
D O I
10.1053/gast.2001.22470
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background & Aims: Growth hormone (GH) is used as therapy for inflammatory bowel disease (IBD), but the specific effects on intestine are unknown. Transgenic mice overexpressing GH (MT1-bGH-TG) were used to test whether increased plasma GH levels alter inflammation or crypt damage during dextran sodium sulfate (DSS)induced colitis, Methods: MT1-bGH-TG and wild-type (WT) littermates were given 3% DSS for 5 days followed by up to 10 days of recovery, Colitis and epithelial cell proliferation were evaluated histologically. Plasma insulin-like growth factor (IGF)-I and colonic IGF-I, interleukin (IL)-1 beta, and intestinal trefoil factor (ITF) messenger RNAs (mRNAs) were measured. Results: DSS induced similar disease onset in MT1-bGH-TG and WT, More MT1-bGH-TG survived than WT. By recovery day 7, MT1-bGH-TG had less inflammation and crypt damage, elevated plasma IGF-I, and increased colonic ITF expression relative to WT. Colonic IL-1 beta was elevated in DSS-treated MT1-bGH-TG and WT, but IL-1 beta mRNA abundance correlated with disease only in WT, MT1-bGH-TG showed earlier increases in epithelial cell proliferation than WT during recovery but only WT showed atypical repair. Conclusions: GH does not alter susceptibility to acute DSS-induced colitis but enhances survival, remission of inflammation, and mucosal repair during recovery, GH therapy may be beneficial during active IBD by improving mucosal repair.
引用
收藏
页码:925 / 937
页数:13
相关论文
共 42 条
[1]   Involvement of interleukin-1 in the development of ulcerative colitis induced by dextran sulfate sodium in mice [J].
Arai, Y ;
Takanashi, H ;
Kitagawa, H ;
Okayasu, I .
CYTOKINE, 1998, 10 (11) :890-896
[2]   Surgical therapy for ulcerative colitis and Crohn's disease [J].
Becker, JM .
GASTROENTEROLOGY CLINICS OF NORTH AMERICA, 1999, 28 (02) :371-+
[3]   One year growth hormone replacement therapy does not alter colonic epithelial cell proliferation in growth hormone deficient adults [J].
Beentjes, JAM ;
van Gorkom, BAP ;
Sluiter, WJ ;
de Vries, GE ;
Kleibeuker, JH ;
Dullaart, RPF .
CLINICAL ENDOCRINOLOGY, 2000, 52 (04) :457-462
[4]   A NEW TREATMENT FOR PATIENTS WITH SHORT-BOWEL SYNDROME - GROWTH-HORMONE, GLUTAMINE, AND A MODIFIED DIET [J].
BYRNE, TA ;
PERSINGER, RL ;
YOUNG, LS ;
ZIEGLER, TR ;
WILMORE, DW .
ANNALS OF SURGERY, 1995, 222 (03) :243-255
[5]  
COOPER HS, 1993, LAB INVEST, V69, P238
[6]  
Dieleman LA, 1998, CLIN EXP IMMUNOL, V114, P385
[7]   Nutritional issues in inflammatory bowel disease [J].
Dieleman, LA ;
Heizer, WD .
GASTROENTEROLOGY CLINICS OF NORTH AMERICA, 1998, 27 (02) :435-+
[8]   Low-dose recombinant human growth hormone increases body weight and lean body mass in patients with short bowel syndrome [J].
Ellegard, L ;
Bosaeus, I ;
Nordgren, S ;
Bengtsson, BA .
ANNALS OF SURGERY, 1997, 225 (01) :88-96
[9]   Experimental models to study molecular mechanisms underlying intestinal inflammation [J].
Elson, CO ;
Cong, Y ;
Brandwein, S ;
Weaver, CT ;
McCabe, RP ;
Mähler, M ;
Sundberg, JP ;
Leiter, EH .
INTESTINAL PLASTICITY IN HEALTH AND DISEASE, 1998, 859 :85-95
[10]   Inflammatory bowel disease: Etiology and pathogenesis [J].
Fiocchi, C .
GASTROENTEROLOGY, 1998, 115 (01) :182-205